Zacks - Soligenix Inc (SNGX) SNGX: Exited 2016 with relatively strong balance sheet, Long-term positive data reported from Phase II SGX942 reported; Phase III of SGX-301 initiated in collaboration with NORD and CLF.

Report

Zacks

SNGX: Exited 2016 with relatively strong balance sheet, Long-term positive data reported from Phase II SGX942 reported; Phase III of SGX-301 initiated in collaboration with NORD and CLF.

28/03/2017 12 EN

Underlying

Soligenix Inc

See profile

US8342233074 NASDAQ Stock Market United States

Provider

Zacks

Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

See profile

Other Reports on these Companies

Zacks

SNGX: Q&A on COVID-19 Vaccine TM CandidateCiVax ...

June 22, 2020 June 22, 2020 6 EN

Zacks

SNGX: Publication on Immune Correlates Â® for RiVax ...

May 20, 2020 May 20, 2020 7 EN

Zacks

SNGX: Continued Treatment with SGX301 Leads to Increased Efficacy in CTCL...

May 5, 2020 May 5, 2020 6 EN

PBSV: Steady as she goes

July 24, 2020 July 24, 2020 5 EN

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

July 9, 2020 July 9, 2020 7 EN

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

July 2, 2020 July 2, 2020 7 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SNGX: Exited 2016 with relatively strong balance sheet, Long-term positive data reported from Phase II SGX942 reported; Phase III of SGX-301 initiated in collaboration with NORD and CLF.

SNGX: Q&A on COVID-19 Vaccine TM CandidateCiVax ...

SNGX: Publication on Immune Correlates Â® for RiVax ...

SNGX: Continued Treatment with SGX301 Leads to Increased Efficacy in CTCL...

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe